Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

BACKGROUND: Alectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma (NSCLC) and an anaplastic lymphoma kinase (ALK) fusion. A shorter median progression-free survival (mPFS) was observed when alectinib minimum plasma concentrations during steady state (C(min,SS)) were...

Descripción completa

Detalles Bibliográficos
Autores principales: Meertens, Marinda, Muntinghe-Wagenaar, M. Benthe, Sikkema, Barend J., Lopez-Yurda, Marta, Retèl, Valesca P., Paats, Marthe S., Ter Heine, Rob, Schuuring, Ed, Timens, Wim, Touw, Daan J., van Boven, Job F. M., de Langen, Adrianus. J., Hashemi, Sayed M. S., Hendriks, Lizza E. L., Croes, Sander, van den Heuvel, Michel M., Dingemans, Anne-Marie C., Mathijssen, Ron H. J., Smit, Egbert F., Huitema, Alwin D. R., Steeghs, Neeltje, van der Wekken, Anthonie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035072/
https://www.ncbi.nlm.nih.gov/pubmed/36969063
http://dx.doi.org/10.3389/fonc.2023.1136221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035072/
https://www.ncbi.nlm.nih.gov/pubmed/36969063
http://dx.doi.org/10.3389/fonc.2023.1136221

Ejemplares similares